throbber
(12) United States Patent
`Marks et al.
`
`(10) Patent No.2
`(45) Date of Patent:
`
`US 9,006,224 B2
`Apr. 14, 2015
`
`US009006224B2
`
`(54) NEUROENDOCRINE TUMOR TREATMENT
`
`(75)
`
`Inventors: Peter Wayne Marks, Woodbridge, CT
`(US);DaV1d Lebwohl, Mad1s0n,NJ
`(US)
`
`(73) Assignee: Novartis AG, Basel (CH)
`s
`otice:
`u ect to an
`1SC aimer, t e term 0 t
`*
`N '
`s bj
`yd’
`1
`'
`h
`f iii
`patent is extended or adjusted under 35
`Uisici 154(1)) by 589 days.
`
`(21) Appl. No.:
`.
`(22) PCT F11ed3
`
`12/094,173
`
`N0V- 20: 2006
`
`(86) PCT No;
`
`PCT/EP2006/068656
`
`§ 371 (C)(1),
`(2), (4) Date: May 19, 2008
`
`(87)
`
`pCT pub. N0‘; W02007/057457
`
`PCT Pub. Date: May 24, 2007
`
`(65)
`
`Prior Publication Data
`US 2008/0255029 Al
`Oct. 16, 2008
`
`Foreign Application Priority Data
`(30)
`NOV 21 2005
`(GB)
`0523658 3
`"""""""""""""""""" "
`'
`’
`'
`Jan. 19, 2006
`(GB) ................................. .. 0601082.1
`Feb. 10,
`. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ..
`Apr. 21, 2006
`(GB) ................................. .. 0607942.0
`May 10, 2006
`(GB) ................................. .. 0609272.0
`
`May 18’ 2006
`(GB)
`06099121
`Sep. 14, 2006
`(EP) ................................... .. 06120660
`
`(51)
`
`(2006.01)
`(200601)
`(2006.01)
`
`Int- 0-
`A6IK 31/436
`A61K 38/31
`A61K 45/06
`(52) U'S' Cl‘
`CPC ~~~~~~~~~~~~~ ~~ A61K 38/31 (2013-01); A61K 31/436
`(2013.01);A6IK45/06 (2013.01)
`(58) Field of Classification Search
`CPC .................................................... A61K 31/436
`See application file for Complete Search history‘
`
`(56)
`
`References Cited
`
`U.S. PATENT DOCUMENTS
`
`5,538,739 A
`2002/0183239 A1
`
`7/1996 Bodmer et al.
`12/2002 Gibbons, Jr. et al.
`
`2002/0183240 A1
`2003/0008923 A1
`2004/0175339 A1
`2005/0187184 A1
`
`12/2002 Gibbons
`1/2003 Dukart et al.
`9/2004 sherman
`8/2005 Gibbons, Jr. et al.
`
`EP
`RU
`WO
`WO
`
`FOREIGN PATENT DOCUMENTS
`0 462 071
`i2/i991
`2264405 C2
`11/2005
`97/05167
`2/1997
`97/47317
`12/1997
`
`W0
`W0
`
`W0
`W0
`W0
`
`W0
`
`W002/055019
`02/080975
`
`3/2002
`10/2002
`
`WO2004/004644 A2
`2004/078133
`2005/082411
`
`2006/071966
`
`A2
`
`1/2004
`9/2004
`9/2005
`
`7/2006
`
`OTHER PUBLICATIONS
`Merck Manuals, Pancreatic endocrine tumors, 2009, pp. 1-4.*
`Novartis Data Sheet. Novartis, GEP NE tumors, published online on
`Apr. 2005, pp. i_2.*
`Arnold et al. Chapter 15 of “Gastrointestinal and Liver Tumors” by
`Wolfgang Scheppack, 2004, Chapter 15, pp. 195-233.*
`Asano Takayuki, et al: “The rapamycin analog CCI-779 is a potent
`inhibitor of pancreatic cancer cell proliferation”, Biochemical and
`Biophysical Research Communications, 331, May 27, 2005, pp.
`295-302.
`Boulay Anne, et al: “Antitumor efficacy of intermittent treatment
`sshedules With the rapamycin derivative RAD001 correlates With
`prolonged inactivation ofribosonial protein S6 kinase 1 in peripheral
`blood mononuclear cells”, Cancer Research, 64, Jan. 1, 2004, pp.
`252-261.
`Boulay Anne, et al: “Prolonged effect of the rapamycin derivative
`lI){1ADd0i)1 or111p7§0tS6(i<ir1_ase(:i:ictivity in tumors, slt<in and iateriplllircilral
`oo
`ymp oc
`es
`erive
`rom a syngeneic ra pancrea ic
`or
`model: correlation With efficacy of intermittent dosing schedules”,
`Proceedings of the American Association for Cancer Research
`gnnuaii/If"’tt_1nga 43tsP~ 602~_
`_ d
`d
`d th 1_
`1
`H d th
`urns
`ris iane, e
`:
`pamycin-in uce en 0
`e ia ce
`ea
`and tumor vessel thrombosis potentiate cytotoxic therapy against
`pancreatic cancer”Clinical Cancer Research, vol. 10, Mar. 15, 2004,
`pp. 21094199.
`an orally active
`Terence, et al: “In Vivo activity
`rapamycin derivative in experimental tumor models”, Proceedings of
`t11\ieAr2r:)<e0ricanz;1ssoc1at10n for Cancer ReseanehAnnna1Meenng,43.
`ar.
`, p.
`.
`Stephan Susann, et al: “Effect ofrapamycin alone and in combination
`with antiangiogenesis therapy in an Ofihotopic model Ofhuman pan_
`creatic cancer”, Clinical Cancer Research, vol. 10, 200-10-15, pp.
`6993-7000, 2004.
`Townsley Carol A., et al: “Evaluation of adverse events experienced
`by older patients participating in studies of molecularly targeted
`ia\gen7ts glonei o£6combi2n1aAtii1ori 1,4(9Zancer Therapy: Clinical, vol. 12,
`0~
`5
`PL 5
`5 PR
`'
`~
`Database Medline: Canobbio L. et
`al:
`“Use of long-acting
`soniatostatin analog, lanreotide, in neuro-endocrine tumors.” Oncol-
`ogy reports, vol. 1, No. 1 Jan. 1994 p. 129-131.
`Hofsli, Eva et al., “Expression of Chiriomogranin A and Somatostatin
`fr‘fI°1:I1’(§°rS ‘V“0I1’*‘i‘;jf*1“°f§5“_21J7;3‘°i1(1)j)2aM°1e°“1‘““dCe““1‘“E“d°'
`Dorlanrillllustrated Ila/Ifedical Dictionary, “Dorlands Illustrated Medi-
`cal Dictionary”, Elsevier Saunders, 2012, Ed. 32nd 955.
`The Merck Index; 15111 edition; 2013; p. 718.
`Hanin et al., “Effect of Interferon-a Treatment .
`Nuclear Medicine, No. 52, 2011; pp. 580-585.
`
`. 7’; The Journal of
`
`* Cited by examiner
`
`. 7 Samira Jean_LOuiS
`E
`P .
`’””‘”y ’‘‘””’”e’
`.
`(74) Attorney, Agent, or Firm — Gregory Ferraro
`
`ABSTRACT
`(57)
`A method for treating endocrine tumors by administration of
`an mTOR inhibitor, optionally in combination With another
`drug
`
`3 Claims, N0 Drawings
`
`Par Pharm., Inc.
`Exhibit 1001
`Page 001
`
`Par Pharm., Inc.
`Exhibit 1001
`Page 001
`
`

`
`US 9,006,224 B2
`
`1
`NEUROENDOCRINE TUMOR TREATMENT
`
`The present invention relates to organic compounds, more
`specifically to the use of mTOR inhibitors in neuroendocrine
`tumor treatment.
`
`5
`
`An mTOR inhibitor as used herein is a compound which
`targets intracellular mTOR (“mammalian Target of rapamy-
`cin”). mTOR is a family member of phosphatidylinositol
`3-kinase (P13-kinase) related kinase. The compound rapa-
`mycin and other mTOR inhibitors inhibit mTOR activity via
`a complex with its intracellular receptor FKBP12 (FK506-
`binding protein 12). mTOR modulates translation of specific
`mRNAs via the regulation of the phosphorylation state of
`several different
`translation proteins, mainly 4E-PB1,
`P70S6K (p70S6 kinase 1) and eEF2.
`Rapamycin is a known macrolide antibiotic produced by
`Slreplomyces hygroscopicus of formula
`
`
`
`Other mTOR inhibitors include rapamycin derivatives, for
`example including rapamycin substituted in position 40 and/
`or 16 and/or 32.
`
`Examples of other mTOR inhibitors include 40-O-alkyl-
`raparnycin derivatives, e.g. 40-O-hydroxyalkyl-rapamycin
`derivatives, for example 40-O-(2-hydroxy)-ethyl-rapamycin
`(everolimus),
`rapamycin derivatives which are substituted in 40 position by
`heterocyclyl, e.g. 40-epi-(tetrazolyl)-rapamycin (also known
`as ABT578),
`32-deoxo-raparnycin derivatives and 32-hydroxy-rapamycin
`derivatives, such as 32-deoxorapamycin,
`16-O-substituted rapamycin derivatives such as 16-pent-2-
`ynyloxy-32-deoxoraparnycin,
`16-pent-2-ynyloxy-32(S or
`R)-dihydro-rapamycin, or 16-pent-2-ynyloxy-32(S or R)-di-
`hydro-40-O-(2-hydroxyethyl)-raparnycin,
`rapamycin derivatives which are acylated at the oxygen in
`position 40, e.g. 40- [3 -hydroxy-2-(hydroxy-methyl)-2-meth-
`ylpropanoate]-rapamycin (also known as CCI779 or tem-
`sirolimus),
`rapamycin derivatives (also sometimes designated as rapal-
`ogs) as disclosed in WO9802441 orWO0l 14387, e.g. includ-
`ing AP23573, such as 40-O-dimethylphosphinyl-raparnycin,
`compounds disclosed under the name biolimus (biolimus
`A9), including 40-O-(2-ethoxy)ethyl-raparnycin, and com-
`pounds disclosed under the name TAFA-93, AP23464,
`AP23675 orAP23841; or
`
`10
`
`15
`
`20
`
`25
`
`30
`
`35
`
`40
`
`45
`
`50
`
`55
`
`60
`
`65
`
`2
`
`mTOR inhibitors as e.g. disclosed in WO2004101583,
`WO9205179, WO9402136, WO9402385 and WO9613273.
`Preferred mTOR inhibitors include
`
`rapamycin, and/or
`40-O-(2-hydroxyethyl)-raparnycin, and/or
`32-deoxorapamycin, and/or
`16-pent-2-ynyloxy-32-deoxoraparnycin, and/or
`16-pent-2-ynyloxy-32 (S or R)-dihydro-rapamycin, and/or
`16-pent-2-ynyloxy-32 (S or R)-dihydro-40-O-(2-hydroxy-
`ethyl)-rapamycin, and/or
`40- [3 -hydroxy-2 - (hydroxy-methyl)-2-methylpropanoate] -
`rapamycin (also known as CCI779) and/or
`40-epi-(tetrazolyl)-rapamycin (also known as ABT578), and/
`or
`
`the so-called rapalogs, e.g. as disclosed in WO9802441,
`WO0114387
`and WO0364383, AP23573, AP23464,
`AP23675 or AP23841, e.g. AP23573, and/or
`compounds disclosed under the name TAFA-93, and/or
`compounds disclosed under the name biolimus.
`More preferably an mTOR inhibitor is selected from the
`group consisting of rapamycin, and/or
`40-O-(2-hydroxyethyl)-raparnycin, and/or
`32-deoxorapamycin, and/or
`16-pent-2-ynyloxy-32-deoxoraparnycin, and/or
`16-pent-2-ynyloxy-32 (S or R)-dihydro-rapamycin, and/or
`16-pent-2-ynyloxy-32 (S or R)-dihydro-40-O-(2-hydroxy-
`ethyl)-rapamycin, and/or
`40- [3 -hydroxy-2 - (hydroxy-methyl)-2-methylpropanoate] -
`rapamycin (also known as CCI779) and/or
`40-epi-(tetrazolyl)-rapamycin (also known as ABT578), and/
`or
`
`AP23573,
`such as 40-O-(2-hydroxyethyl)-rapamycin.
`mTOR inhibitors, on the basis of observed activity, have
`been found to be useful e.g. as immunosuppressant, e.g. in the
`treatment of acute allograft rejection and have additionally
`potent antiproliferative properties which make them useful
`for cancer chemotherapy, particularly for the treatment of
`solid tumors, especially of advanced solid tumors.
`Endocrine, e.g. neuroendocrine tumors (NETs), are found
`in the endocrine system. Carcinoid tumors, are a special type
`of tun1or, generally classified as endocrine tumors. Carcinoid
`tumors belong to the family of neuroendocrine tumors which
`derive from the neuroendocrine cell system. In the intestinal
`tract, these tumors develop deep in the mucosa, growing
`slowly and extending into the underlying submucosa and
`mucosal surface. This results in the formation of small firm
`
`nodules, which bulge into the intestinal lumen. Pancreatic
`neuroendocrine tumors (islet cell tumors), which were for-
`merly classified as APUDomas (tumors of the amine precur-
`sor uptake and decarboxylation system), comprise less than
`half of all neuroendicrine tumors and only 1-2% of all pan-
`creatic tumors. Pancreatic NETs can arise either in the pan-
`creas (insulinomas, glucagonomas, nonfunctioning pancre-
`atic NETs, pancreatic NETs causing hypercalcemia) or at
`both pancreatic and extrapancreatic sites (gastrinomas, VlPo-
`mas, somatostatinomas, GRFomas). The hormones secreted
`by pancreatic NETs depend upon the cell of origin and are
`physiologically involved in a network of autocrine, paracrine,
`endocrine and neurotransmitter communication. While hor-
`
`mone secretion is not observed in all cases ofpancreatic NET,
`the apparently “nonfunctioning” (i.e., non-secreting) pancre-
`atic NETs tend to be more aggressive and present with symp-
`toms of tumor bulk (see e.g. Barakat et al, Endocrine-related
`cancer 2004; 1121-18 and Tomassetti et al, Ann Oncol 2001;
`12(Suppl 2): S95-S99).
`
`Par Pharm., Inc.
`Exhibit 1001
`Page 002
`
`Par Pharm., Inc.
`Exhibit 1001
`Page 002
`
`

`
`US 9,006,224 B2
`
`3
`All pancreatic NETs, with the exception of 90% of insuli-
`nomas, have long-term metastatic potential. Most are overtly
`malignant at the time of diagnosis, and 60% or more present
`with liver metastases. The most common cause of death from
`
`pancreatic NET is hepatic failure (Warner R R P, Gastroen-
`terology 2005; 128: 1 668-16842005).
`In a recent review, the 5-year survival rate in a series of 83
`consecutive patients with pancreatic NETs has been reported
`to be 55.3% which points to an unmet medical need for
`continued treatment in patients with pancreatic NETs whose
`disease has progressed following 1 or more courses of che-
`motherapy.
`Carcinoid tumors have historically been classified, accord-
`ing to their point of origin in embryonic development, as
`arising from the foregut (e.g., bronchial, pulmonary or gastric
`carcinoid), midgut (e.g., small intestine or appendiceal carci-
`noid), or hindgut (e.g., rectal carcinoid), see e.g. Kulke M.,
`Cancer Treatment Reviews 2003; 29:363-370.
`Primary foregut tumors are confined to the thymus, lung,
`stomach, and duodenum. Midgut carcinoids are located in the
`distal ileum, cecum, and proximal colon. One interesting
`subset ofthis group is appendiceal carcinoids, which are often
`benign and rarely give rise to metastatic disease. The midgut
`carcinoids dominate the malignant carcinoid tumors, particu-
`larly when the carcinoid syndrome is present.
`The hindgut tumors are primarily located in the distal colon
`and rectum.
`
`Data suggest that the incidence of pulmonary and gastric
`carcinoid has increased in the past two decades.
`According to histopathologic criteria, carcinoids can be
`divided into typical (TC) and atypical (AC) carcinoids. Car-
`cinoids can be placed in a spectrum of neuroendocrine
`tumors, ranging from low-grade malignant TC to intermedi-
`ate AC to high-grade large-cell neuroendocrine carcinoma
`and small-cell lung carcinoma.
`Carcinoid lung tumors e.g. include neuroendocrine carci-
`noma, Kulchitsky cell carcinoma (KCC), bronchial carcinoid
`tumors, bronchial adenomas, typical carcinoids, atypical car-
`cinoids, carcinoid syndrome, small-cell carcinomas, Kul-
`chitsky cells, argentaffin cells, pulmonary carcinoids, neu-
`roendocrine lung tumors, (primary) pulmonary neoplasms,
`bronchopulmonary carcinoid tumors, lung neoplasms, lung
`cancers, pulmonary cancers, intrabronchial mass.
`Bronchial carcinoid tumors may originate from the neuro-
`secretory cells ofbronchial mucosa and were previously clas-
`sified as bronchial adenomas. Bronchial carcinoids are now
`
`classed as low-grade malignant neoplasms because of their
`potential to cause local invasion, their tendency for local
`recurrence, and their occasional metastases to extrathoracic
`sites.
`
`Bronchial carcinoids belong to a group of neuroendocrine
`tumors, which cover a range of tumors ranging from bron-
`chial carcinoid at one of the spectrum, with a small cell
`carcinoma, or possibly large cell neuroendocrine tumors at
`the other end. They demonstrate a wide range of clinical and
`biologic behaviors, including the potential to synthesize and
`secrete peptide hormones and neuroamines, particularly
`adrenocorticotropic hormone (ACTH), serotonin, somatosta-
`tin, and bradykinin.
`Bronchial carcinoid tumors may arise from Kulchitsky
`cells (argentafiin cells) within the bronchial mucosa. The
`predominant distribution of cells are believed to occur at the
`bifurcation of the lobar bronchi. These cells are neurosecre-
`
`tory cells, which belong to the amine precursor uptake and
`decarboxylation (APUD) system. They have the capacity to
`synthesize serotonin (5-hydroxytryptamine), 5-hydroxytryp-
`
`10
`
`15
`
`20
`
`25
`
`30
`
`35
`
`40
`
`45
`
`50
`
`55
`
`60
`
`65
`
`4
`
`tophan, ACTH, norepinephrine, bombesin, calcitonin, antidi-
`uretic hormone (ADH), and bradykinin.
`Large-cell neuroendocrine carcinoma of the lung is a
`newly recognized climcopathologic entity, which is distinct
`from small-cell carcinoma and has a poor prognosis.
`Typical carcinoid tumors of the lung represent the most
`well differentiated and least biologically aggressive type of
`pulmonary neuroendocrine tumor. These tumors characteris-
`tically grow slowly and tend to metastasize infrequently.
`Atypical carcinoid tumors have a more aggressive histologic
`and clinical picture. They metastasize at a considerably
`higher rate than do typical carcinoid tumors. Carcinoid syn-
`drome has been reported in association with very large bron-
`chopulmonary carcinoid tumors or in the presence of meta-
`static disease. It is noted much less frequently in association
`with carcinoids of pulmonary origin than those originating
`within the gastrointestinal tract. Endocrine syndromes found
`in association with small cell carcinoma ofthe lung are found
`less commonly with carcinoid tumors of the lung; however,
`some endocrine abnormalities have been attributed to both
`
`typical and atypical pulmonary carcinoid tumors.
`Carcinoid tumors of the GI tract may display an aggressive
`biology similar to that ofadenocarcinomas, particularly when
`they are located in the colon, stomach, and small intestine, see
`e.g. Modlin I M et al, Gastroenterology 2005; 128: 1717-
`1751. For small-intestinal carcinoids, which are the most
`frequent cause of carcinoid syndrome due to metastatic dis-
`ease in the liver, the incidence ofmetastasis increases propor-
`tionally with the size of the primary tumor (Tomassetti et al
`2001, ibidem).
`The incidence and survival data available suggest that
`clinical trials ofnew anticancer agents inpatients with midgut
`carcinoid tumors may provide the opportunity to address an
`unmet medical need in a growing segment of the population
`of patients with carcinoids.
`Carcinoid syndrome is caused by hypersecretion ofnumer-
`ous hormone products by the tumor cells, including kinins,
`prostaglandins, substance P, gastrin, corticotrophin and chro-
`mogranin A (see e.g. Davis et al, Gynecology & Obstetrics
`1973; 137:637-644). Various endocrine or neuroendocrine
`syndromes can be initial clinical manifestations of either
`typical or atypical pulmonary carcinoid tumors. Carcinoid
`syndrome, hypercortisolism and Cushing syndrome, inap-
`propriate secretion ofADH, increased pigmentation second-
`ary to excess MSH, and ectopic insulin production resulting
`in hypoglycemia are some ofthe endocrinopathies that can be
`produced by a pulmonary carcinoid tumor in a patient who is
`otherwise asymptomatic.
`The most common symptoms are hemoptysis, cough,
`recurrent pulmonary infection, fever, chest discomfort and
`chest pain, unilateral wheezing, and shortness of breath,
`flushing and diarrhea. Paraneoplastic syndromes are rare and
`include carcinoid syndrome, Cushing’s
`syndrome, and
`ectopic growth hormone-releasing hormone secretion.
`Other less frequent symptoms include cardiac manifesta-
`tions secondary to fibrosis ofthe endocardium (Jacobsen M B
`et al, Eur Heart J 1995; 16:263-268) which may result in
`valvular regurgitation (valvular heart disease), with varying
`degrees of heart failure in patients with cardiac manifesta-
`tions. Wheezing or asthma-like symptoms, pellagra-like skin
`lesions with hyperkeratosis, abdominal pain, telangiectasias
`and paroxysmal hypotension are also seen in a number of
`patients. Patients with pulmonary carcinoid often show
`symptoms like recurrent pneumonia, cough, hemoptysis or
`chest pain. The majority ofpulmonary carcinoid tumors are in
`the perihilar area. Ectopic secretion of corticotropin from
`pulmonary carcinoid tumors may also account for Cushing’s
`
`Par Pharm., Inc.
`Exhibit 1001
`Page 003
`
`Par Pharm., Inc.
`Exhibit 1001
`Page 003
`
`

`
`US 9,006,224 B2
`
`5
`syndrome. Early in the course, symptoms are usually episodic
`and may be provoked by stress, catecholamines, and inges-
`tion of food or alcohol. During acute paroxysms, systolic
`blood pressure typically falls 20 to 30 mmHg. Endocardial
`fibrosis can cause Valvular heart disease, usually affecting the
`proximal side of the tricuspid and pulmonary Valves and
`leading to tricuspid insufiiciency and secondary right-sided
`heart failure.
`
`A recent review of chemotherapeutic treatment of carcino-
`ids reports that the sensitivity of these tumors to various
`cytotoxic drugs is low, and combination does not increase
`their effectiveness. Based on their review of various combi-
`
`including dacarbazine/fluorouracil or
`nation therapies,
`5-fluorouracil/epirubicin, the authors conclude that that they
`are unable to recommend a specific chemotherapeutic regi-
`men for patients with well-differentiated neuroendocrine
`malignancies ofthe GI tract (Arnold R, RinkeA et al, Clinical
`Gastroenterology 2005; l9(4):649-656). The apparent refrac-
`toriness of such tumors to currently available therapies points
`to an unmet medical need for treatment in this patient popu-
`lation.
`
`As part of the endocrine system that regulates hormones,
`the pituitary gland controls many of the other glands through
`secretion. Our “master gland,” the pituitary makes some hor-
`mones, but also acts as an intermediary between the brain and
`other endocrine glands. Our hormones and the pituitary gland
`accomplish many homeostatic and specialized functions, like
`bone growth and uterine contractions.
`Neurons carry messages regarding the production of hor-
`mones between the pituitary gland and the hypothalamus.
`Both are located at the base of the brain, nestled in a rounded
`part of bone, carefully protected. They are connected by a
`bunch of neurons called the infundibulum. Together, they
`work to regulate all the hormones that circulate in the blood-
`stream, controlling things like growth and hair pigmentation.
`Hormones are the long-distance messangers that can inform
`cells when to become active or stay dormant. The pituitary
`gland controls the thyroid, adrenal glands, ovaries and testes,
`even though it’s only the size of a pea.
`There are different parts of the pituitary gland that have
`selective functions. The posterior lobe, called the neurohypo-
`physis, releases the hormones vasopressin and oxytocin, but
`doesn’t produce them. Vasopressin is an anti-diuretic that
`controls how the kidneys absorb water. Oxytocin is a special
`hormone only present during childbirth to speed contractions.
`The anterior lobe of the pituitary gland is called the adeno-
`hypophysis. It produces a variety of hormones, such as pro-
`lactin that stimulates lactation in women. Melanocyte spurs
`the body to produce melanin for skin and hair pigmentation.
`Follicle-stimulating hormone indicates where and when hair
`should grow during development. The very important growth
`hormone controls bone growth to determine height, espe-
`cially active during adolescence. Hormones control glands as
`well. The thyroid reacts to thyrotropin, the adrenal glands are
`stimulated by adrenocorticotropin, and the sex glands are
`affected by luteinizing hormone. The pituitary gland is
`responsible for many stages and aspects of our maturation.
`Pituitary tumors are in general noncancerous (benign),
`comprising only 10 percent of brain tumors. However,
`because ofthe location ofthe pituitary gland, at the base ofthe
`skull, a pituitary tumor grows upward. And, eventually, many
`pituitary tumors press against the optic nerves, causing vision
`problems. Symptoms vary depending upon what type of
`tumor is growing and what area of the pituitary gland is
`affected. Pituitary tumors can cause symptoms that are
`caused by excess production ofpituitary hormones and symp-
`toms caused by reduced production of pituitary hormones.
`
`10
`
`15
`
`20
`
`25
`
`30
`
`35
`
`40
`
`45
`
`50
`
`55
`
`60
`
`65
`
`6
`Other symptoms may be due to the proximity ofthese tumors
`to local brain structures, such as the optic nerves leading to
`loss of vision. Each individual also experiences symptoms
`differently, and the symptoms many resemble other condi-
`tions or medical problems
`The most common type of pituitary tumor is called a clini-
`cally nonfunctioning tumor, because patients do not have the
`classic pituitary syndromes from excess hormones, such as in
`acromegaly. These types oftun1ors may be detected during an
`evaluation of an incidental problem. A clinically nonfunc-
`tioning tumor may cause hypopituitarism, or an underactive
`pituitary gland, which may lead to failure of sexual function,
`reduced sperm production, and cessation of a woman’ s men-
`strual period, along with fatigue.
`Another common pituitary tumor is called a prolactinoma,
`a benign tumor that produces the prolactin hormone. Prolac-
`tin stimulates breast milk production after childbirth. Women
`with a prolactinoma may have reduced or absent menstrual
`cycles along with breast milk production.
`An uncommon pituitary tumor causes excess growth hor-
`mone production (a hormone necessary for normal childhood
`growth) resulting in acromegaly. In adults, such tumors lead
`to excessive somatic growth and multiple systemic, medical
`consequences. Another uncommon pituitary tumor results in
`Cushing’s disease, a disorder of excess steroid production.
`Multiple endocrine neoplasia type 1 (MEN 1) is a relatively
`uncommon inherited disease. Individuals who inherit the
`
`gene for MEN 1 have an increased chance of developing
`overactivity and enlargement of certain endocrine glands.
`The endocrine glands most commonly affected by MEN 1 are
`the parathyroid, pancreas, and pituitary glands. Almost every-
`one who inherits MEN 1 develops overactivity ofthe parathy-
`roid glands (hyperparathyroidism) at some stage in their life.
`The other endocrine glands become overactive less fre-
`quently, however, people who inherit MEN 1 will usually
`develop overactivity in more than one endocrine gland. Over-
`activity in different endocrine glands may occur simulta-
`neously or at separate times during a persons life. MEN 1 can
`lead to overactivity and enlargement of the three endocrine
`glands listed above (the endocrine glands which start with the
`letter “P”). People who inherit the gene for MEN 1 are pre-
`disposed to developing an overactivity in hormone produc-
`tion from the parathyroid glands, pituitary gland and pancreas
`(that is why physicians will measure hormones in the blood to
`check for overproduction of each specific hormone).
`Increased hormone production is usually associated with
`enlargement of these glands. Endocrine gland enlargement
`and hormone overproduction does not usually occur in all
`areas of an endocrine gland at the same point in time. Some
`parts of overactive endocrine glands grow more rapidly than
`others, and produce more hormone than other parts of the
`same gland. The parts ofan endocrine gland which grow most
`rapidly become “lumpy”. These lumps are usually benign.
`Benign lumps in endocrine glands are known as adenomas.
`Adenomas are benign (not cancerous), and do not spread to
`other parts of the body. Pituitary adenomas (pituitary tumors,
`nervous system tumor) can lead to nerve damage, growth
`disturbances, and changes in hormonal balance. Symptoms of
`pituitary adenomas can vary considerably, largely depending
`on whether or not the tumor is secreting one or more of a
`variety of hormones. Even if the tumor is not producing any
`hormones,
`its location at the base of the brain can cause
`significant symptoms. Symptoms may e.g. include double or
`blurred vision, loss of peripheral vision, sudden blindness,
`headache, dizziness, loss of consciousness, nausea, weak-
`ness, unexplained weight changes, amenorrhea, erectile dys-
`function in men, decreased sexual desire, especially in men,
`
`Par Pharm., Inc.
`Exhibit 1001
`Page 004
`
`Par Pharm., Inc.
`Exhibit 1001
`Page 004
`
`

`
`US 9,006,224 B2
`
`7
`growth of skull, hands, and feet, deepening of voice, changes
`in facial appearance (due to changes in facial bones), wider
`spacing ofteeth, joint pain, increased sweating, purple stretch
`marks on the abdomen, increased hair growth, fat deposits
`where the neck meets the spine, moodiness or depression,
`easy bruising, palpitations (rapid or irregular heartbeat),
`tremor, increased appetite, feeling warm or hot, difficulty
`falling asleep, anxiousness, frequent bowel movements, lump
`in the front of the neck (enlarged thyroid).
`It was found that mTOR inhibitors may be used for the
`treatment of such special type of tumors
`In accordance with the particular findings the present
`invention provides in several aspects:
`1.1 A method for treating endocrine tumors, comprising
`administering to a subject in need thereof a therapeutically
`effective amount of an mTOR inhibitor.
`
`1.2 A method for inhibiting growth of endocrine tumors,
`comprising administering to a subject in need thereof a
`therapeutical effective amount of an mTOR inhibitor.
`1.3 A method for inhibiting or controlling endocrine tumors,
`comprising administering to a subject in need thereof a
`therapeutically effective amount of an mTOR inhibitor.
`1.4 A method for inducing endocrine tumor regression, e.g.
`tumor mass reduction, comprising administering to a sub-
`ject in need thereof a therapeutical effective amount of an
`mTOR inhibitor.
`
`1.5 A method for treating endocrine tumor invasiveness or
`symptoms associated with such tumor growth, comprising
`administering to a subject in need thereof a therapeutically
`effective amount of an mTOR inhibitor.
`
`1.6 A method for preventing metastatic spread of endocrine
`tumors or for preventing or inhibiting growth of microme-
`tastasis, comprising administering to a subject in need
`thereof a therapeutically effective amount of an mTOR
`inhibitor.
`1.7 A method for the treatment of a disorder associated with
`endocrine tumors, comprising administering to a subject in
`need thereof a therapeutically effective amount of an
`mTOR inhibitor.
`1.8 The use of an mTOR inhibitor for the manufacture of a
`medicament for use in any method of 1.1 to 1.7 above.
`1.9 A pharmaceutical composition comprising an mTOR
`inhibitor in association with at least one pharmaceutically
`acceptable excipient, e.g. appropriate carrier and/or dilu-
`ent, e.g. including fillers, binders, disintegrants, flow con-
`ditioners, lubricants, sugars or sweeteners, fragrances, pre-
`servatives, stabilizers, wetting agents and/or emulsifiers,
`solubilizers, salts for regulating osmotic pressure and/or
`buffers; for use in any method or use of 1.1 to 1.7 above.
`Endocrine tumors as indicated herein e. g. include neuroen-
`docrine tumors, e.g. including carcinoid tumors, pancreatic
`neuroendocrine tumors and tumors in parathyroid, pancreas,
`and pituitary glands.
`Carcinoid tumors as indicated herein e.g. include typical
`and atypical carcinoids, ranging from low-grade malignant
`typical to intermediate atypical to high-grade large-cell neu-
`roendocrine carcinoma and small-cell lung carcinoma; e.g.
`including carcinoids arising from the
`foregut e.g., bronchial, pulmonary or gastric carcinoids,
`e.g. including primary foregut tumors confined to the
`thymus, lung, stomach, and duodenum; e.g. carcinoid
`tumors of the GI tract, e.g. located in the colon, stomach
`or small intestine, e.g. small-intestinal carcinoids, e.g.
`including
`midgut, e.g., small intestine or appendiceal carcinoids, e.g.
`located in the distal ileum, cecum, and proximal colon,
`or
`
`hindgut, e.g., rectal carcinoids.
`
`10
`
`15
`
`20
`
`25
`
`30
`
`35
`
`40
`
`45
`
`50
`
`55
`
`60
`
`65
`
`8
`Carcinoid lung tumors as indicated herein e.g. include
`neuroendocrine
`carcinoma, Kulchitsky cell
`carcinoma
`(KCC) (Kulchitsky cells, argentaffin cells), bronchial carci-
`noid tumors, bronchial adenomas, e.g. including bronchial
`adenomas such as a small cell carcinoma and large cell neu-
`roendocrine tumors, typical carcinoids or atypical carcinoids
`associated with large bronchopulmonary carcinoid tumors or
`small-cell carcinomas, pulmonary carcinoids, neuroendo-
`crine lung tumors, large-cell neuroendocrine carcinoma of
`the lung, (primary) pulmonary neoplasms, bronchopulmo-
`nary carcinoid tumors, lung neoplasms, lung cancers, pulmo-
`nary cancers, intrabronchial mass.
`Pancreatic neuroendocrine tumors as indicated herein e.g.
`include islet cell
`tumors, APUDomas,
`insulinomas, glu-
`cagonomas, nonfunctioning pancreatic NETs, pancreatic
`NETs associated with hypercalcemia, gastrinomas, VlPo-
`mas, somatostatinomas, GRFomas.
`Endocrine or neuroendocrine tumor symptoms as indi-
`cated herein e.g. include hemoptysis, cough, recurrent pul-
`monary infection, fever, chest discomfort and chest pain,
`unilateral wheezing, shortness of breath, flushing and diar-
`rhea, endocrine or neuroendocrine syndromes carcinoid syn-
`drome, e.g.
`including manifestations of either typical or
`atypical pulmonary carcinoid tumors, Cushing’s syndrome,
`inappropriate secretion ofADH, increased pigmentation sec-
`ondary to excess MSH, and ectopic insulin production result-
`ing in hypoglycemia, ectopic growth hormone-releasing hor-
`mone secretion, ectopic secretion of corticotropin, cardiac
`manifestations secondary to fibrosis of the endocardium (en-
`docardial fibrosis), valvular regurgitation (valvular heart dis-
`ease),
`tricuspid insufficiency, secondary right-sided heart
`failure, wheezing or asthma-like symptoms, pellagra-like
`skin lesions with hyperkeratosis, abdominal pain, telang-
`iectasias and paroxysmal hypotension, recurrent pneumonia,
`cough, chest pain.
`Tumors in parathyroid, pancreas and pituitary glands as
`indicated herein, e.g. include pituitary tumors, nervous sys-
`tem tumor, such as adenomas, multiple endocrine neoplasia
`type 1 (MEN 1).
`Pituitary tumor symptoms as indicated herein include
`symptoms that are associated with excess production of pitu-
`itary hormones and symptoms caused by reduced production
`of pituitary hormones, loss of vision, clinically nonfunction-
`ing tumor, e.g. associated with hypopituitarism underactive
`pituitary gland, e.g. associated with failure of sexual function,
`reduced sperm production, and cessation of a woman’ s men-
`strual period, along with fatigue, prolactinoma, a benign
`tumor that produces the prolactin hormone, acromegaly, e.g.
`associated with excessive somatic growth and multiple sys-
`temic, medical consequences, Cushing’s disease, nerve dam-
`age, growth disturbances, changes in hormonal balance,
`double or blurred vision, loss of peripheral vision, sudden
`blindness, headache, dizziness, loss of consciousness, nau-
`sea, weakness, unexplained weight changes, amenorrhea,
`erectile dysfunction in men, decreased sexual desire, espe-
`cially in men, growth of skull, hands, and feet, deepening of
`voic

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket